Provided by Tiger Trade Technology Pte. Ltd.

ZYMEWORKS INC (US)

22.72
+0.70003.18%
Volume:575.66K
Turnover:13.05M
Market Cap:1.70B
PE:-26.95
High:23.06
Open:22.38
Low:22.34
Close:22.02
52wk High:28.49
52wk Low:9.03
Shares:74.84M
Float Shares:38.30M
Volume Ratio:1.07
T/O Rate:1.50%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.8432
EPS(LYR):-1.6177
ROE:-18.46%
ROA:-9.98%
PB:5.31
PE(LYR):-14.04

Loading ...

Zymeworks Inc. Files Initial Statement of Beneficial Ownership for SVP & Chief Medical Officer Sabeen Mekan

Reuters
·
Feb 03

Zymeworks Inc. Joins Leerink Global Healthcare Conference for Fireside Chat

Reuters
·
Jan 27

Assessing Zymeworks (ZYME) Valuation After Major Leadership And Board Reshuffle

Simply Wall St.
·
Jan 27

Zymeworks Inc. unveils strategy focused on growing royalty portfolio and advancing novel medicines for difficult-to-treat diseases

Reuters
·
Jan 21

Zymeworks Inc. Files Initial Beneficial Ownership Statement for Mark Hollywood, EVP & Chief Operating Officer

Reuters
·
Jan 14

Zymeworks Inc. Files Initial Statement of Beneficial Ownership for Director Brian N. Cherry

Reuters
·
Jan 14

BUZZ-U.S. STOCKS ON THE MOVE-AbCellera Biologics, Zymeworks, Silver miners

Reuters
·
Jan 12

Zymeworks Chief Finance, Medical, Scientific Officers Leaving in Executive Reorg

Dow Jones
·
Jan 12

Zymeworks Inc. unveils pipeline progress and partnership milestones in latest corporate presentation

Reuters
·
Jan 12

Zymeworks Inc. Appoints New Executives and Board Member

Reuters
·
Jan 12

Zymeworks Inc - Leone Patterson Will Depart From CFO Role During Q1 2026

THOMSON REUTERS
·
Jan 12

Zymeworks Inc - Galbraith Assumes Role of Acting CFO

THOMSON REUTERS
·
Jan 12

Press Release: Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy

Dow Jones
·
Jan 12

Zymeworks outlines priorities, outlook for 2026

TIPRANKS
·
Jan 12

Zymeworks Inc. Outlines Strategy to Drive Long-Term Value Through Royalty Growth, Strategic Acquisitions, and Internal R&D Innovation Supported by Strengthened Financial Foundation

Reuters
·
Jan 12

BRIEF-Zymeworks Outlines Strategic Priorities And Outlook For 2026

Reuters
·
Jan 12

Zymeworks Outlines Strategic Priorities and Outlook for 2026

THOMSON REUTERS
·
Jan 12

Zymeworks Inc: Global Phase 1 Clinical Trial Investigating ZW191 in Solid Tumors Is Ongoing With Dose Optimization of ZW191 in Ovarian Cancer

THOMSON REUTERS
·
Jan 12

Zymeworks: up to $440 Mln in Milestone Payments Eligible to Be Earned Related to Regulatory Approvals of Ziihera in Gea in United States, Europe, Japan, & China

THOMSON REUTERS
·
Jan 12

Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME), Pacira Pharmaceuticals (PCRX) and Beta Bionics, Inc. (BBNX)

TIPRANKS
·
Jan 09